Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
05 10월 2023 - 5:05AM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that it will host a conference call and webcast on Friday, October
13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The
event will feature trial investigator, Miguel Villalona-Calero,
M.D, Medical Oncologist and Director of Early Therapeutics, City of
Hope, along with Kronos Bio management, who will discuss the
current treatment landscape for patients with MYC-dependent solid
tumors, provide an overview of KB-0742 and further discuss the
poster to be presented at the AACR-NCI-EORTC International
Conference in Boston, Mass. KB-0742 is the company’s internally
discovered, highly selective, oral cyclin dependent kinase 9 (CDK9)
inhibitor being developed to treat MYC-dependent solid tumors.
A live webcast of the conference call can be
accessed under “Events & Presentations” on the investors
section of the Company’s website at
ir.kronosbio.com/events-presentations. To participate in the live
call, please register using this link. It is recommended that
participants register at least 15 minutes in advance of the call.
Once registered, participants will be informed of the dial-in
numbers and PIN. An archived webcast will be available following
the event.
Presentation information
Poster Title: A First-In-Human
Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of
Tolerability and Clinical Activity
Presenter: Miguel
Villalona-Calero, M.D, City of Hope
Abstract #: B159
Date and Time: Poster Session B |
Friday, October 13, 12:30 pm-4:00 pm ET, Level 2, Exhibit Hall
D
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that is
advancing two investigational compounds in clinical trials for
patients with cancer. The company is developing the CDK9 inhibitor
KB-0742 as a treatment for MYC-dependent solid tumors and other
transcriptionally addicted solid tumors and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The company’s scientific focus is on developing
medicines that target the deregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a
research facility in Cambridge, Mass. For more information, visit
www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Sarah Connors,
Vice President of Investor Relations and Corporate
CommunicationsKronos Bio857-290-7305sconnors@kronosbio.com
Agency Contact:Brendan Strong,
Managing DirectorArgot Partners
212-600-1902kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Kronos Bio (NASDAQ:KRON)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024